Csl Limited

Csl Behring Gmbh

Csl Behring Lengnau Ag

Abbott Laboratories Corporation

Ludwig Institute for Cancer Research Limited

Con Panousis

Andrew Donald Nash

Michael Wilson

Marc Nolte

Veronika Rayzman

Matthew Hardy

Stefan Schmidbauer

Kirsten Edwards

Manuel Baca

Felicity Meredith Dunlop

Steve Dower

Dallas Hartman

Arna Andrews

Kerstin Emmrich

Arna Elizabeth Andrews

Lloyd J Old

Gerd J Ritter

Elisabeth Stockert

Antony Wilks Burgess

Eugene Maraskovsky

Karlheinz Peter

Webster K Cavenee

Edouard Collins Nice

Christoph Renner

Achim Jungbluth

Terrance Grant Johns

Anne Murray

George Mark

Gino Luigi Vairo

Nicholas Wilson

Andrew Mark Scott

Malgorzata Wygrecka

Catherine Owczarek

Nick Wilson

Samantha Busfield

Yung-Chih Chen

Peter Collins

Sabine Rauth

Andrew Hammet

Huei-Jen Su Huang

Hamid Hosseini

Chao-Guang Chen

Elizabeth Stockert

Kirsten Mae Edwards

Matthew Philip Hardy

Terrance Grant Jonhs

Huei-Jen Huang

Anthony Wilks Burgess

Gerd Ritter

The present disclosure provides proteins comprising antigen binding domains of antibodies that bind to human granulocyte-colony stimulating factor receptor.

Nucleic acids encoding antibodies against human granulocyte-colony stimulating factor receptor (G-CSFR) and method of expressing encoded protein

The present disclosure provides a CD131-binding protein comprising an antigen binding domain of an antibody, wherein the antigen binding domain binds to or specifically binds to CD131 and neutralizes signaling by interleukin (IL) 3, IL-5 and granulocyte-macrophage colony stimulating factor (GM-CSF), and uses thereof.

CD131 binding proteins and uses thereof

The invention relates to an inhibitor of Factor XII (FXII) for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia/reperfusion injury in native or transplant kidneys and/or acute kidney injury, a kit for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia/reperfusion injury in native or transplant kidneys, acute kidney injury, renal fibrosis as a result of rejection of a kidney transplant/allograft, and/or fibrosis of a kidney transplant/allograft as a result of rejection or recurrent underlying disease comprising one inhibitor of Factor XII, and an anti-Factor XII (FXII) antibody or antigen binding fragment thereof for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia/reperfusion injury in native or transplant kidneys and/or acute kidney injury comprising one inhibitor of Factor XII.

Use of a FXIIa-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease

A serum albumin variant, or functional fragment thereof, comprising one or more amino acid substitutions selected from (i) glycine, isoleucine, lysine, methionine, phenylalanine, tryptophan, tyrosine, valine and leucine substituted for glutamine at position (522); (ii) valine substituted for alanine at position (552); and (iii) alanine, glutamic acid, histidine, serine, lysine and arginine substituted for glycine at position (572).

Human serum albumin variants and uses thereof

The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.

Methods of administering inhibitory anti-factor XII/XIIa monoclonal antibodies

The present disclosure relates to a method of treating or preventing atherosclerosis in a subject by administering an inhibitor of FXII.

Method of treating atherosclerosis

The present invention provides a modified polypeptide which binds Factor VIII. The polypeptide comprises truncated von Willebrand Factor (VWF) which comprises a sequence as shown in SEQ ID NO:3 or a fragment thereof or a sequence 90% identical thereto, wherein the truncated VWF comprises at least one modification in comparison to SEQ ID NO: 3 in at least one position selected from the group consisting of SI, S3, LI 8, V42, S43, K149, N248, S279, V320, T325, Q395 and K418.

Mutated truncated von Willebrand Factor

The present invention provides a modified polypeptide which binds Factor VIII. The modified polypeptide comprises a sequence as shown in SEQ ID NO:3 in which the sequence comprises at least one modification at a position selected from the group consisting of L18, V42, K149, N248, S279, V320, T325, Q395 and K418 such that the modified polypeptide binds to Factor VIII with an off rate lower than a reference polypeptide comprising an unmodified SEQ ID NO:3.

Mutated von Willebrand factor

Methods of administering inhibitory anti-factor XII/XIIA monoclonal antibodies

The present disclosure provides antibodies that bind to interleukin-3 receptor alpha chain and uses thereof.

Humanized anti-interleukin 3 receptor alpha chain antibodies

Nucleic acids encoding inhibitory anti-factor XII/XIIa monoclonal antibodies

The present disclosure provides a method for treating lupus, Sj&#xf6;rgen's syndrome or scleroderma, the method comprising administering to the mammal an immunoglobulin which binds an interleukin 3 receptor &#x3b1; (IL-3R&#x3b1;) chain and which depletes or at least partly eliminates plasmacytoid dendritic cells (p DCs) and basophils to which it binds.

Compositions and methods for targeting type 1 interferon producing cells

The present disclosure provides methods for producing expression constructs comprising linking a plurality of unlinked nucleic acids, including a nucleic acid encoding a marker protein.

Method of cloning nucleic acid

Inhibitory anti-factor XII/XIIA monoclonal antibodies and their uses

Growing community of inventors

Bundoora, Australia

Con Panousis